SillaJen's 'BAL0891' Selected for Poster Presentation at ESMO 2026
Participation in All Three Major Global Oncology Conferences This Year
On July 30, SillaJen announced that the results of its Phase 1 clinical study of its next-generation anti-cancer pipeline 'BAL0891' have been selected for poster presentation at the European Society for Medical Oncology (ESMO 2026).
ESMO is considered one of the top three global oncology societies, alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). The event is scheduled to be held in Madrid, Spain from October 23 to 27, local time.
With this acceptance by ESMO, SillaJen has achieved the milestone of participating in all three of the world's leading oncology conferences this year. This provides an opportunity to demonstrate the technology and significant clinical achievements of BAL0891 to the global market from multiple perspectives.
Notably, at the end of May, SillaJen released initial clinical data of BAL0891 at the annual meeting of the American Society of Clinical Oncology (ASCO 2026), drawing attention from the academic community with successful results such as the identification of the recommended Phase 2 dose (RP2D).
Building on these achievements, SillaJen plans to present Phase 1 research results on the safety and efficacy of BAL0891 monotherapy, as well as a combination therapy with paclitaxel, in patients with advanced solid tumors at ESMO.
A SillaJen representative stated, "BAL0891 is gaining recognition for its technological capabilities as we participate in all three major global oncology conferences this year," adding, "We will do our best to share meaningful research outcomes at ESMO as well."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, SillaJen is currently conducting Phase 1 clinical trials of BAL0891 in four separate cohorts for patients with solid tumors and acute myeloid leukemia (AML) at major clinical centers in the United States and Korea.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.